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Abstract
Objectives. Limitations in the methods available for identifying cardiac involvement and accurately quan-
tifying disease activity in the idiopathic inflammatory myopathies (IIMs) may contribute to poor outcomes.
We investigated the utility of different serum muscle damage markers [total creatine kinase (CK), cardiac
troponin T (cTnT) and cardiac troponin I (cTnI)] to address these issues.
Methods. We assessed disease activity and cardiac involvement using the International Myositis
Assessment and Clinical Studies Group core set measures in 123 participants with confirmed adult-
onset IIM from the UK and Denmark. Total CK, cTnT and cTnI were measured. Associations were as-
sessed using logistic regression and Spearman’s ranked correlation.
Results. Cardiac involvement (n= 18) was associated with higher cTnI levels, independent of overall dis-
ease activity [adjusted odds ratio 1.03 (95% CI 1.01, 1.05); P= 0.002]. An abnormal cTnI had the highest
specificity and positive predictive value for cardiac involvement (95% and 62%, respectively). In those with
a normal CK but elevated cTnT or cTnI, an association with increased disease activity scores was
observed. Serum cTnT correlated with the physician (r= 0.39) and patient-assessed (r= 0.28) global
visual analogue scales and HAQ (r= 0.41) more strongly than CK or cTnI levels. cTnT was the only
marker to correlate with manual muscle testing scores (r=0.24).
Conclusion. Serum cTnI testing may have a role in screening for cardiac involvement in IIMs. Abnormal
levels of serum cTnT and cTnI are associated with increased disease activity, including in those with a
normal CK.
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Rheumatology key messages
. In the idiopathic inflammatory myopathies, serum troponin testing may improve disease activity assessments.
. In the idiopathic inflammatory myopathies, abnormal troponin I had the highest specificity for cardiac involvement.
. In the idiopathic inflammatory myopathies, troponin T levels correlated most strongly with disease activity.
Introduction
The idiopathic inflammatory myopathies (IIMs) are multi-
system autoimmune diseases characterized primarily by
skeletal muscle inflammation. Limitations in current meth-
ods for detecting early signs of organ-specific flares can
delay timely commencement or escalation of treatment
and may contribute to poor outcomes. Disease activity
in IIMs can be quantified using the International Myositis
Assessment and Clinical Studies Group (IMACS) core set
measures (CSMs). These include the measurement of dif-
ferent serum muscle damage markers (“muscle
enzymes”), total creatine kinase (CK), lactate dehydrogen-
ase, aldolase or transaminases [1]. As total CK can be
normal in patients with active IIM, the isolated use of this
parameter can be misleading, but it remains common
practice [2].
Cardiac involvement occurs in up to 75% of patients
with IIM, is often subclinical, represents a major cause
of morbidity and mortality and is sometimes only identified
post-mortem [3]. Several methods are used in clinical
practice to screen for cardiac involvement in IIM, including
electrocardiography, echocardiography and contrast-
enhanced cardiac MRI [4]. So called cardiac-specific
serum muscle damage markers [cardiac troponin T
(cTnT) and cardiac troponin I (cTnI)] may have a role, but
can lack specificity for cardiac disease in IIM, especially
the cTnT, which is often elevated in those with skeletal
muscle disease without cardiac involvement [5, 6].
In this cross-sectional study, we evaluated the useful-
ness of serum cTnT and cTnI levels in screening for car-
diac involvement and in quantifying disease activity in
patients with IIM. Comparison is made with the use of
serum total CK and the potential for using cTnT or cTnI
as the second serum muscle damage marker in the
IMACS disease activity CSMs assessment.
Methods
Cases
We performed an analysis of data pooled from two co-
horts, one in the UK and one in Denmark (n= 123). Data
regarding some of the Danish cohort has been previously
published as part of separate studies [4, 7]. Details of pa-
tient identification procedures at each site are contained
in the supplementary data, section ‘Patient identification’,
available at Rheumatology online.
Assessment
Each case was assessed using the IMACS disease activity
CSMs. This included manual muscle testing-8 (MMT-8),
HAQ disability index (HAQ-DI), physician and patient-as-
sessed global disease activity visual analogue scales
(VASs) and an extramuscular disease assessment using
the Myositis Disease Activity Assessment Tool (MDAAT) [1].
Cases also supplied blood for measurement of serum
total CK, cTnT and cTnI (supplementary data, section
‘Laboratory assays’, available at Rheumatology online).
The results were not available to clinicians at the time of
their performing clinical assessments. Normalization of
CK and cTnI levels was performed to allow comparison
of results from different assays (supplementary data, sec-
tion ‘Laboratory assays’, available at Rheumatology
online). A result was deemed abnormal if the value was
above the upper limit of the laboratory reference range (for
cTnT) or normalized reference range (for CK and cTnI).
Cardiac involvement
Cardiac involvement was determined as per the cardiac
domain of the MDAAT, the agreed upon tool for evaluating
the presence and extent of extramuscular involvement in
IIM [8]. The MDAAT has been partially validated, performs
well in terms of interrater reliability and is used in IIM clin-
ical trials, including the recently published Rituximab in
Myositis study [9]. In the current study, the assessment
could include consideration of any recently performed
cardiac investigations (e.g. electrocardiography or echo-
cardiogram), but additional investigations were not per-
formed. Cardiac involvement was deemed as present
when the cardiac VAS score on the MDAAT was >0.
Statistical analysis
Data processing and analysis was performed using STATA
for Windows version 13.0 (StataCorp, College Station, TX,
USA). Normally distributed data were summarized by cal-
culation of means and standard deviations (S.D.). Non-nor-
mally distributed data were summarized using medians
and interquartile ranges (IQRs). Convergent construct val-
idity of the serum muscle damage markers was assessed
by Spearman’s ranked correlation with other aspects of
disease activity. A correlation coefficient (r) >0.70 was
considered as representing a strong relationship,
0.250.70 a moderate relationship and <0.25 a weak rela-
tionship. Logistic regression was used to assess associ-
ations with cardiac involvement and abnormal serum
muscle damage markers. All models were adjusted for
cohort (i.e. UK or Denmark). The physician-completed
global disease activity VAS was used to adjust for overall
IIM disease activity where specified. P-values <0.05 were
considered significant.
Ethics and consent
Full informed consent was obtained from all participating
patients. The study was completed in full conformance
with the principles of the Declaration of Helsinki. In the
UK, ethical approval was obtained from the Health
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Research Authority (East Midlands  Leicester Central
Research Ethics Committee, reference 14/EM/1248). We
also conformed to Good Clinical Practice and the laws
and regulations of the UK. In Denmark, the study
was approved by the local ethics committee (reference
S-20100022).
Results
A total of 123 cases were analysed (Denmark 79, UK 44;
supplementary Table S1, available at Rheumatology
online). Overall, 32% (39/123) of cases had DM, 28% (34/
123) had PM, 30% (37/123) had anti-synthetase syndrome,
7% (8/123) had immune-mediated necrotizing myopathy
and 4% (5/123) had IIM-CTD overlap disease (supplemen-
tary Table S2, available at Rheumatology online). The mean
age was 58 years (S.D. 14), 66% (81/123) of cases were
female and 94% (116/123) were Caucasian.
Screening for cardiac involvement
Eighteen cases were deemed to have cardiac involvement
[15% (18/121); MDAAT not completed in two cases]
(Table 1). Higher disease activity levels (physician global
disease activity VAS, HAQ and extramuscular global VAS)
were associated with cardiac involvement. No difference
in diagnostic subtype, serotype, age, disease duration,
gender or smoking status between those with or without
cardiac involvement was detected.
The cTnI level correlated most strongly with the cardiac
disease activity VAS (Table 2). An increased risk of cardiac
involvement was associated with increasing serum levels
of cTnT and cTnI, although this was independent of overall
disease activity only for cTnI [adjusted odds ratio (OR)
1.03 (95% CI 1.01, 1.05), P= 0.002].
An abnormal cTnI had the highest specificity and positive
predictive value (PPV) for cardiac involvement but the
lowest sensitivity (Table 1). Cardiac involvement was only
present in 23% (11/48) of those with an abnormal total CK
and 21% (15/71) of those with an abnormal cTnT, com-
pared with 62% (8/13) of those with an abnormal cTnI.
When stratifying serum muscle damage marker levels ac-
cording to the type of cardiac involvement identified (as per
the MDAAT: myocardial, pericardial, arrhythmia or sinus
tachycardia), only myocardial disease was associated
with increasing levels of cTnT and cTnI [for cTnT: adjusted
OR 1.00 (95% CI 1.00, 1.01), P= 0.006; for cTnI: adjusted
OR 1.01 (95% CI 01.00, 1.02), P= 0.015] (supplementary
Table S3, available at Rheumatology online).
Correlation between serum muscle damage marker
levels and disease activity
The cTnT levels correlated most strongly with the phys-
ician global VAS, the patient global VAS, the HAQ disabil-
ity index (HAQ-DI) and the manual muscle testing score,
outperforming CK and cTnI in all cases (Table 2). cTnT
was the only serum marker to correlate with the MMT-8
score and cTnI was the only marker to correlate with the
extramuscular global VAS. The total CK level had the
weakest correlations with the physician global VAS, the
patient global VAS and the HAQ-DI and showed no sig-
nificant correlation with the extramuscular global VAS, the
cardiac disease VAS or the MMT-8.
The added value of troponin testing
In 40% (29/73) of cases that had a normal total CK, the
cTnT was elevated. In these cases, the abnormal cTnT
was associated with lower MMT-8 scores [median 74
(IQR 7278) vs 78 (7579); adjusted OR 0.83 (95% CI
0.71, 0.96); P= 0.011] and higher patient-assessed
global disease activity VAS [4.8 (IQR 2.77.4) vs 2.6
(1.85.4); adjusted OR 1.30 (95% CI 1.04, 1.62);
P= 0.019]. Despite the elevated cTnT, an increased risk
of cardiac involvement was not seen when compared with
those with normal cTnT [14% (4/29) vs 7% (3/44); adjusted
OR 2.20 (95% CI 0.45, 10.78); P= 0.332].
The cTnI was elevated in 7% (5/73) of those with a normal
total CK. In such cases, an abnormal cTnI was associated
with increasing patient-assessed global disease activity VAS
[median 7.8 (IQR 7.38.1) vs 3.3 (1.95.5); adjusted OR 2.54
(95% CI 1.25, 5.18); P= 0.010], and with cardiac involve-
ment [29% (2/7) vs 5% (3/66); adjusted OR 10.36 (95% CI
1.22, 87.72); P= 0.032].
Discussion
Interpretation and implications
The cTnI levels were significantly increased in those with
cardiac involvement and this was independent of overall
disease activity. An abnormal cTnI had the highest PPV for
cardiac involvement and was the only damage marker to
correlate significantly with the extramuscular global VAS.
This suggests that the cTnI level provides information
about a different facet of IIM disease activity compared
with CK and cTnT and is perhaps most useful as a screen-
ing tool for cardiac involvement. However, the low sensi-
tivity for cardiac involvement implies that a normal cTnI
level does not exclude it. In contrast, the low specificity of
cTnT and CK for cardiac involvement may generate un-
necessary concern about such involvement. Those with
cardiac involvement had significantly worse overall dis-
ease activity, suggesting that clinicians should have a
low threshold for considering the potential for cardiac in-
volvement in patients with highly active IIM.
We have demonstrated that, of the muscle damage
markers tested, cTnT levels correlated most strongly
with IIM disease activity. We also identified significantly
worse aspects of disease activity in those with normal
CK but abnormal cTnT or cTnI, confirming the notion
that the use of CK in isolation to assess IIM disease ac-
tivity can be misleading.
Elevations of cTnT and the CK-MB fraction (both con-
ventionally used as cardiac damage markers) are
observed frequently in those with IIM in the absence of
cardiac involvement [1012]. Potential explanations for
this include the existence of subtle subclinical cardiac in-
volvement, as supported by timekinetic analysis, which
suggests that elevated cTnT in IIM is of cardiac origin in at
least some cases [13].
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Cross-reactivity of the cTnT assay with skeletal muscle
troponin T (sTnT) is another possible explanation for ele-
vations seen in IIM. However, very low levels of cross-re-
activity are reported for the current generation of assays
[12, 14]. Finally, it has been shown that regenerating skel-
etal muscle fibres can express cTnT and CK-MB, thus
elevations in IIM may actually originate from skeletal
muscle undergoing repair rather than from myocardium
[5, 14, 15]. Importantly, as cTnI does not share this char-
acteristic, elevated levels should be assumed to have
arisen from the myocardium [16, 17].
Strengths and limitations
This study included thorough assessment of cases using
the IMACS disease activity CSMs toolkit and is the
largest study to use this panel of serum muscle
damage markers. Researchers were blinded to serum
muscle damage marker levels during patient clinical as-
sessments, thus minimizing the potential for bias.
However, there are several limitations. The study
lacked a gold standard to define cardiac involvement,
relying on assessment using the partially validated
MDAAT, without additional investigations being per-
formed. However, during phase two of the MDAAT val-
idation study, the sensitivity, specificity and PPV for
active cardiac disease was 100% [8]. Despite this, our
study may underestimate the presence of cardiac in-
volvement, particularly subtle subclinical disease. It is
also possible that subtle abnormalities on any investiga-
tions performed may not have been identified. Future
studies may be improved by the use of skeletal muscle
and cardiac MRI to understand the relative contributions
TABLE 1 Disease activity and serum muscle damage marker levels stratified by the presence of cardiac involvement
Cardiac involvement
(n = 18)a
No cardiac involvement
(n = 103) Odds ratio P-value
Diagnostic subcategory, n (%)
DM 5 (28) 34 (33) 0.79 (0.19, 3.20) 0.736
Anti-synthetase syndrome 6 (33) 29 (28) 1.15 (0.31, 4.28) 0.655
PM 5 (28) 29 (28) Referent —
IMNM 2 (11) 6 (6) 1.62 (0.21, 12.72) 0.698
MyositisCTD overlap 0 (0) 5 (5) 1 —
Autoantibody profile, n (%)
Myositis-specific antibody 11 (61) 49 (48) 2.25 (0.57, 8.92) 0.249
Myositis-associated antibody 4 (22) 24 (23) 1.67 (0.34, 8.24) 0.530
Seronegative 3 (17) 30 (29) Referent —
Disease duration, median (IQR), years 2.8 (0.412) 5.2 (1.310) 0.96 (0.87, 1.06) 0.412
Age, mean (S.D.), years 58 (18) 58 (13) 1.00 (0.97, 1.04) 0.879
Female gender, n (%) 12 (67) 67 (65) 1.08 (0.37, 3.08) 0.909
Ever smoked, n (%) 9 (50) 44 (43) 1.40 (0.50, 3.93) 0.521
Disease activity measures, median (IQR)
Physician global disease activity VAS 3.2 (1.06.5) 1.4 (0.83.3) 1.24 (1.03, 1.49) 0.021
Patient global disease activity VAS 5.2 (1.77.9) 4.3 (2.26.1) 1.12 (0.91, 1.38) 0.291
HAQ-DI 1.6 (0.42.4) 0.5 (01.3) 2.69 (1.42, 5.07) 0.002
Extramuscular global VASc 2.2 (0.64.0) 0.9 (0.41.9) 1.30 (1.05, 1.61) 0.017
Manual muscle testing 76 (6879) 77 (7379) 0.93 (0.85, 1.01) 0.074
Serum muscle damage markers, median (IQR)
Total CK, IU/Ld 497 (95771) 134 (81331) 1.00 (0.99, 1.00) 0.465
Abnormal total CK, n (%) 11 (61) 37 (36) Sensitivity 61%
Specificity 64%
PPV 23%
cTnT, ng/l 91 (29156) 17 (848) 1.00 (1.00, 1.01) 0.013
Abnormal cTnT, n (%) 15 (83) 56 (54) Sensitivity 83%
Specificity 46%
PPV 21%
cTnI, ng/ld 25 (5128) 5 (016) 1.03 (1.01, 1.05) 0.001
Abnormal cTnI, n (%) 8 (44) 5 (5) Sensitivity 44%
Specificity 95%
PPV 62%
Cardiac involvement was defined as a score >0 on the cardiac VAS component of the MDAAT. Abnormal levels of serum
muscle damage markers are defined as a value greater than the upper limit of the laboratory reference range. Two cases are
omitted from this table because the cardiac domain of the MDAAT was not completed. ORs are adjusted for country of origin
of the participants and are derived from logistic regression. Bold values indicate P<0.05. aEighteen patients had cardiac
involvement. Using categories defined in the MDAAT with the following frequencies: myocarditis, 12; sinus tachycardia, 6;
arrhythmia, 4; pericarditis, 1 (some patients had multiple types). bAdjusted for cohort (i.e. UK or Denmark). cA component of
the MDAAT. dNormalized values shown. IMNM: immune-mediated necrotizing myopathy.
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to serum muscle damage marker elevations and the re-
lationship between subclinical (e.g. purely radiologically
evident) cardiac involvement and serum muscle damage
marker elevations in IIM. While we did not include ana-
lysis of the intent-to-treat aspect of the MDAAT cardiac
assessment, high correlation has been demonstrated
between this and the severity assessment (r = 0.94) [8].
As data were pooled from separate studies, this creates
the possibility of systematic bias influencing the results due
to differing practices in each centre. However, similar pro-
portions of cardiac involvement were identified in both co-
horts [16% (7/44) in the UK and 14% (11/77) in Denmark].
We reported the PPV for cardiac involvement (i.e. the prob-
ability that subjects with an abnormal serum muscle damage
marker truly have the cardiac involvement). Therefore, in set-
tings where the prevalence of cardiac involvement and may
differ, the PPV we defined may be less applicable.
Conclusion
We have demonstrated the potential benefits of measur-
ing serum cTnI and cTnT levels in patients with IIM,
enhancing the disease activity assessment and assisting
with the identification of cardiac involvement.
Where an abnormal cTnI is encountered in IIM, this
should alert one to the possibility of cardiac involvement.
In such cases, and in patients with highly active IIM, clin-
icians should have a low threshold for arranging further
investigations to evaluate this possibility. In cases with a
normal CK but abnormal cTnT levels, significantly
increased levels of disease activity were identified without
an increased frequency of cardiac involvement.
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